Literature DB >> 18191015

European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II.

Susanne Krege1, Jörg Beyer, Rainer Souchon, Peter Albers, Walter Albrecht, Ferran Algaba, Michael Bamberg, István Bodrogi, Carsten Bokemeyer, Eva Cavallin-Ståhl, Johannes Classen, Christoph Clemm, Gabriella Cohn-Cedermark, Stéphane Culine, Gedske Daugaard, Pieter H M De Mulder, Maria De Santis, Maike de Wit, Ronald de Wit, Hans Günter Derigs, Klaus-Peter Dieckmann, Annette Dieing, Jean-Pierre Droz, Martin Fenner, Karim Fizazi, Aude Flechon, Sophie D Fosså, Xavier Garcia del Muro, Thomas Gauler, Lajos Geczi, Arthur Gerl, Jose Ramon Germa-Lluch, Silke Gillessen, Jörg T Hartmann, Michael Hartmann, Axel Heidenreich, Wolfgang Hoeltl, Alan Horwich, Robert Huddart, Michael Jewett, Johnathan Joffe, William G Jones, László Kisbenedek, Olbjørn Klepp, Sabine Kliesch, Kai Uwe Koehrmann, Christian Kollmannsberger, Markus Kuczyk, Pilar Laguna, Oscar Leiva Galvis, Volker Loy, Malcolm D Mason, Graham M Mead, Rolf Mueller, Craig Nichols, Nicola Nicolai, Tim Oliver, Dalibor Ondrus, Gosse O N Oosterhof, Luis Paz-Ares, Giorgio Pizzocaro, Jörg Pont, Tobias Pottek, Tom Powles, Oliver Rick, Giovanni Rosti, Roberto Salvioni, Jutta Scheiderbauer, Hans-Ulrich Schmelz, Heinz Schmidberger, Hans-Joachim Schmoll, Mark Schrader, Felix Sedlmayer, Niels E Skakkebaek, Aslam Sohaib, Sergei Tjulandin, Padraig Warde, Stefan Weinknecht, Lothar Weissbach, Christian Wittekind, Eva Winter, Lori Wood, Hans von der Maase.   

Abstract

OBJECTIVES: The first consensus report that had been presented by the European Germ Cell Cancer Consensus Group (EGCCCG) in 2004 has found widespread approval by many colleagues throughout the world. In November 2006, the group met a second time under the auspices of the Department of Urology of the Amsterdam Medical Center, The Netherlands.
METHODS: Medical oncologists, urologic surgeons, radiation oncologists as well as pathologists from several European countries reviewed and discussed the data that had emerged since the 2002 conference and incorporated the new data into updated and revised guidelines. As for the first meeting the methodology of evidence-based medicine (EBM) was applied. The results of the discussion were compiled by the writing committee. All participants have agreed to this final update.
RESULTS: The second part of the consensus paper includes the treatment of metastasised disease, residual tumour resection, salvage therapy, follow-up, and late toxicities.
CONCLUSIONS: Whereas the vast majority of the recommendations made in 2004 remain valid 3 yr later, refinements in the treatment of early-stage as well as of advanced-stage testicular cancer have emerged from clinical trials. Despite technical improvements, expert clinical skills will continue to be one of the major determinants for the prognosis of patients with germ cell cancer. In addition, the particular needs of testicular cancer survivors have been acknowledged.

Entities:  

Mesh:

Year:  2007        PMID: 18191015     DOI: 10.1016/j.eururo.2007.12.025

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  60 in total

1.  First salvage treatment of germ cell tumor patients with bone metastases: retrospective analysis of a large international database.

Authors:  Christoph Oing; Anja Lorch; Carsten Bokemeyer; Friedemann Honecker; Jörg Beyer; Lars Arne Berger; Karin Oechsle
Journal:  J Cancer Res Clin Oncol       Date:  2014-11-14       Impact factor: 4.553

2.  Canadian consensus guidelines for the management of testicular germ cell cancer.

Authors:  Lori Wood; Christian Kollmannsberger; Michael Jewett; Peter Chung; Sebastian Hotte; Martin O'Malley; Joan Sweet; Lynn Anson-Cartwright; Eric Winquist; Scott North; Scott Tyldesley; Jeremy Sturgeon; Mary Gospodarowicz; Roanne Segal; Tina Cheng; Peter Venner; Malcolm Moore; Peter Albers; Robert Huddart; Craig Nichols; Padraig Warde
Journal:  Can Urol Assoc J       Date:  2010-04       Impact factor: 1.862

3.  [Testicular germ cell cancer : interdependence between guidelines and a second-opinion system].

Authors:  M Schrader; M Hartmann; S Krege; A Heidenreich; K Miller; L Weissbach
Journal:  Urologe A       Date:  2009-04       Impact factor: 0.639

4.  Management of the post chemotherapy subcentimeter residual mass: the case for observation.

Authors:  Stephen D W Beck; Richard S Foster
Journal:  World J Urol       Date:  2009-07-15       Impact factor: 4.226

Review 5.  Surgical resection of urological tumor metastases following medical treatment.

Authors:  Axel Heidenreich; Stefan Wilop; Michael Pinkawa; Daniel Porres; David Pfister
Journal:  Dtsch Arztebl Int       Date:  2012-09-28       Impact factor: 5.594

6.  Practice Patterns and Impact of Postchemotherapy Retroperitoneal Lymph Node Dissection on Testicular Cancer Outcomes.

Authors:  Solomon L Woldu; Joseph A Moore; Bo Ci; Yuval Freifeld; Timothy N Clinton; Ahmet M Aydin; Nirmish Singla; Krabbe Laura-Maria; Ryan C Hutchinson; James F Amatruda; Arthur Sagalowsky; Yair Lotan; Yull Arriaga; Vitaly Margulis; Yang Xie; Aditya Bagrodia
Journal:  Eur Urol Oncol       Date:  2018-06-06

Review 7.  Clinical stage I seminoma: the case for surveillance.

Authors:  Nathan Lawrentschuk; Neil Fleshner
Journal:  World J Urol       Date:  2009-06-11       Impact factor: 4.226

8.  Mixed testicular germ cell tumor presenting as metastatic pure choriocarcinoma involving multiple lung metastases that was effectively treated with high-dose chemotherapy.

Authors:  Sang-Cheol Lee; Kyoung Ha Kim; Sung Han Kim; Nam Su Lee; Hee Sook Park; Jong-Ho Won
Journal:  Cancer Res Treat       Date:  2009-12-31       Impact factor: 4.679

9.  Update on management of seminoma.

Authors:  Emma J Alexander; Ingrid M White; Alan Horwich
Journal:  Indian J Urol       Date:  2010 Jan-Mar

10.  Observational study of prevalence of long-term Raynaud-like phenomena and neurological side effects in testicular cancer survivors.

Authors:  Marianne Brydøy; Jan Oldenburg; Olbjørn Klepp; Roy M Bremnes; Erik A Wist; Tore Wentzel-Larsen; Erik R Hauge; Olav Dahl; Sophie D Fosså
Journal:  J Natl Cancer Inst       Date:  2009-12-16       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.